API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
Details:
The trial will investigate the company’s Deferoxamine Intradermal Drug Patch (DIDP), for the topical treatment of Sickle Cell Leg Ulcers (SCUs) in support of its Orphan Drug Designation awarded in March of 2019.
Lead Product(s): Deferoxamine Mesylate
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020